KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $285.0 million.

  • Supernus Pharmaceuticals' Total Non-Current Liabilities rose 24.28% to $358.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $358.6 million, marking a year-over-year increase of 24.28%. This contributed to the annual value of $285.0 million for FY2024, which is 5.85% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $285.0 million for FY2024, which was down 5.85% from $302.7 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Total Non-Current Liabilities peaked at $792.8 million during FY2021, and registered a low of $285.0 million during FY2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $302.7 million (2023), whereas its average is $449.7 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 33.06% in 2020, then tumbled by 60.24% in 2023.
  • Supernus Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $713.4 million in 2020, then rose by 11.13% to $792.8 million in 2021, then fell by 3.97% to $761.3 million in 2022, then tumbled by 60.24% to $302.7 million in 2023, then dropped by 5.85% to $285.0 million in 2024.